March 28, 2012
Ajinomoto Pharmaceuticals and Takeda Pharmaceutical announced on March 26 that they submitted applications on the same day for a once-monthly formulation of risedronate sodium hydrate for the treatment of osteoporosis. They expect to obtain approval in the first half of...read more